Navigation Links
Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
Date:1/31/2008

ed to a net loss from continuing operations of $170 million, or a loss of $0.09 per diluted share for the same period in 2006. The 2007 results include charges of $292 million associated with the implementation of the previously announced Productivity Transformation Initiative, an in-process research and development charge of $230 million in connection with the acquisition of Adnexus Therapeutics (Adnexus) and an impairment charge of $275 million on the company's investments in auction rate securities. On a non- GAAP basis excluding specified items, fourth quarter 2007 net earnings from continuing operations were $654 million, or $0.33 per diluted share, compared to $344 million, or $0.18 per diluted share for the same period in 2006.

On January 8, 2008, the company completed the sale of its Medical Imaging business for approximately $525 million, which is presented as a discontinued operation. Included in discontinued operations were fourth quarter net sales of $142 million and $156 million in 2007 and 2006, respectively, and basic and diluted earnings per share of $0.02 in the fourth quarters of 2007 and 2006.

"We are moving forward with important strategic actions that are helping us advance our pipeline, increase productivity and transform to a Next Generation BioPharma company," said James M. Cornelius, chief executive officer, Bristol-Myers Squibb. "Our underlying operating performance this quarter was strong, demonstrating the power of our medicines to help even more people prevail in their fight against serious diseases. The sale of Medical Imaging has strengthened our ability to consider future acquisitions that add to our capabilities, portfolio and pipeline of biotech and specialty medicines. And our Productivity Transformation Initiative, which helps identify ways to operate more efficiently, has spawned a new culture of continuous improvement."

For the twelve months ended December 31, 2007, net sales from continuing operations incre
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine news :

1. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
2. Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors
3. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
4. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
5. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
6. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
7. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
8. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
9. Bristol-Myers Squibb Announces Dividend
10. P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company
11. First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... (PHILADELPHIA) Researchers at the Perelman School of Medicine ... Roswell Park Cancer Institute have received an $8 million ... the effects of photodynamic light therapy (PDT) in patients ... cancer that most often manifests itself in the lining ... exposure to asbestos. The grant will fund a clinical ...
(Date:7/9/2014)... network of signals active in almost all types of ... overdrive, and may help fuel a tumour,s uncontrolled growth, ... Cancer Research, London, identified a molecular trigger responsible for ... the cellular factory that makes the building blocks cancer ... the TOR signalling pathway, called SREBP, controls the flow ...
(Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
(Date:7/9/2014)... Chase Cancer Center paint a relatively optimistic picture of ... that have spread to the chest wall or skin, ... the skin, regardless of size and whether they have ... and called "locally advanced" tumors, suggesting that they ... poor survival. Locally advanced breast cancers of this and ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2
... TO LIFE , , CHICAGO, ... Maria Siemionow, MD, who performed this country,s first face transplant ... Facial transplantation plastic surgery offers great hope for those who ... "The nation,s first face transplant is another great ...
... A new U.S. study has found that being circumcised ... African American men known to have been exposed to ... clinical trials in Africa, where interventional use of adult ... in heterosexual men. The findings of the new study, ...
... , , WASHINGTON, Dec. 17 ... released A Call for Action: Enabling Healthcare Reform Using ... recommendations for the Obama Administration and 111th Congress to harness ... , , "President-elect Obama and ...
... bacteria make their home in the vertebrate gut. Though ... host, othersthe pathogensare unwelcome visitors, causing disease. , ... bacterium. It has evolved sophisticated means of growth, replication, ... body, where it is responsible for most cases of ...
... Bulletin Board: VHGI) the owners of Veriscrip(TM), the,nation,s only ... appointed Anthony Bocchichio to its Advisory Board. , ... 37 years of experience in Federal drug law,enforcement, 25 ... He served,as both Assistant Special Agent in Charge and ...
... record number of course dates for its STARCenter in 2009. ... 22 class sessions focused on pharmacy best practice in relation ... handling. , , ENGLEWOOD, Colo., ... dates for training at its STAR (Skills Training, Academics and ...
Cached Medicine News:Health News:Plastic Surgery Experts Available to Comment on Face Transplant Surgery 2Health News:Circumcision reduces the risk of HIV infection in heterosexual US men 2Health News:HIMSS Releases Health IT Blueprint for Obama Administration and Congress 2Health News:HIMSS Releases Health IT Blueprint for Obama Administration and Congress 3Health News:HIMSS Releases Health IT Blueprint for Obama Administration and Congress 4Health News:Gut instinct: Salmonella bacteria's molecular tactics to cause illness 2Health News:Gut instinct: Salmonella bacteria's molecular tactics to cause illness 3Health News:Gut instinct: Salmonella bacteria's molecular tactics to cause illness 4Health News:VirtualHealth Technologies, Inc. Appoints Former DEA Assistant Administrator to its Advisory Board 2Health News:Baxa Announces 2009 Course Dates for Its STAR Center(R) Training Facility 2Health News:Baxa Announces 2009 Course Dates for Its STAR Center(R) Training Facility 3Health News:Baxa Announces 2009 Course Dates for Its STAR Center(R) Training Facility 4
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Oncology,Inc. (NASDAQ: ZIOP), announced today the presentation of ... being,held in Kos, Greece from June 25-28th, 2007. ... and treatment of multiple,myeloma. ZIOPHARM is presenting darinaparsin ... unique,mechanism of action as well as interim Phase ...
... International Myeloma Workshop -, NORTH HOLLYWOOD, Calif., and ... Myeloma Foundation (IMF) --,supporting research and providing education, ... physicians -- today,said that updated statistics reported at ... survival for a wide,range of myeloma patients. Among ...
Cached Medicine Technology:ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 2ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 3ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 4The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 2The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 3The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: